Access to Medicines for Treating People With Cryptococcal Meningitis

Clin Infect Dis. 2023 Feb 8;76(3):e773-e775. doi: 10.1093/cid/ciac689.

Abstract

Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. World Health Organization guidelines strongly recommend a single high dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.

Keywords: HIV/AIDS; access; cryptococcal meningitis; liposomal amphotericin B; mortality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / therapeutic use
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Fluconazole / therapeutic use
  • Health Services Accessibility
  • Humans
  • Meningitis, Cryptococcal* / drug therapy

Substances

  • Antifungal Agents
  • Fluconazole